Biomarkers for tuberculosis disease activity, cure, and relapse

The Lancet Infectious Diseases

Volumn 10, Issue 2, 2010, Pages 69-70

  Phillips, Patrick Peter John ^a   Davies, Geraint R ^b   Mitchison, Denis A ^c  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BACTERIUM CULTURE; HUMAN; LETTER; LUNG TUBERCULOSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM ANALYSIS; TREATMENT RESPONSE;

AFRICA; ANTITUBERCULAR AGENTS; ASIA; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; GREAT BRITAIN; HONG KONG; HUMANS; MULTICENTER STUDIES AS TOPIC; RECURRENCE; TUBERCULOSIS, PULMONARY;

EID: 74549215139     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70256-7     Document Type: Letter

References (6)

1. Wallis R.S., Doherty T.M., Onyebujoh P., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9 (2009) 162-172
2. Garton N.J., Waddell S.J., Sherratt A.L., et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5 (2008) e75
3. Griffin G.E., Brown M., Gilmore I., et al. UK research trials are on verge of extinction. The Times (London) (Jan 14, 2009). http://www.timesonline.co.uk/tol/comment/letters/article5511067.ece (accessed Dec 15, 2009).
4. Phillips P.J., and Fielding K. Surrogate markers for poor outcome to treatment for tuberculosis: results from extensive multi-trial analysis. Int J Tuberc Lung Dis 12 (2008) S146-S147
5. Prentice R.L. Discussion: surrogate endpoint definition and evaluation. In: Molenberghs G., Buyse M.E., and Burzykowski T. (Eds). The evaluation of surrogate endpoints (2005), Springer, Berlin 341-348
6. Baker S.G., and Kramer B.S. A perfect correlate does not a surrogate make. BMC Med Res Methodol 3 (2003) 16